Tezspire Injection, Solution
Product Images NDC 55513-112

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tezspire (NDC 55513-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton-apfs-sales (Carton Apfs Sales)

Tezepelumab-ekko, also known as "TEZSPIRE", is a prescription drug available for subcutaneous injection only. It comes in a single-dose pre-filled syringe, which must be stored refrigerated between 36°F to 46°F (2°C to 8°C) and protected from light. The drug should not be shaken, frozen, or exposed to heat. The syringe contains 110 mg/mL of the medication. The drug is manufactured by AstraZeneca AB, located in Sodertalie, Sweden, and marketed by both Amgen Inc. and AstraZeneca AB. This information is intended only for medical professionals and is labeled as "Rx only".*

FDA Label Image

Carton (Carton Vial)

FDA Label Image

Figure_1 (Figure1 Needle)

This text appears to be a diagram or visual guide for the proper use and components of a medical syringe. It includes labels for various parts such as the needle guard, plunger head, and finger flange. The diagram also includes a viewing window and label with activation clips and expiration date to ensure safe and effective use.*

FDA Label Image

Figure_2 (Figure 2)

FDA Label Image

Figure_3 (Figure 3)

This is a table presenting probabilities and results of a medical research trial that evaluates the effectiveness of a drug (TEZSPIRE) versus placebo in preventing asthma exacerbations. It shows the probability of the event (asthma exacerbation) being 0.807, and the treatment group divided into two: one group treated with TEZSPIRE, and another treated with placebo. The table also shows the number of participants in each group, and the time to the first asthma exacerbation in weeks.*

FDA Label Image

Figure_4 (Figure 4)

FDA Label Image

Number_3_picture (Number3picture)

FDA Label Image

Number4picture (Number4picture)

FDA Label Image

Number5picture (Number5picture)

FDA Label Image

Number6picture (Number6picture)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.